Emyria Limited

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through through an integrated model of direct clinical services and drug development:

• Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD.
• Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria’s unique therapy and drug development programs.
• Emyria’s Pipeline: One of the world’s largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases as well as highly potent dose forms of Ultra-Pure CBD seeking registration for a range of mental health and neuroscience indications.